RU2005112752A - Производные пиридина в качестве модуляторов рецептора сb2 - Google Patents

Производные пиридина в качестве модуляторов рецептора сb2 Download PDF

Info

Publication number
RU2005112752A
RU2005112752A RU2005112752/04A RU2005112752A RU2005112752A RU 2005112752 A RU2005112752 A RU 2005112752A RU 2005112752/04 A RU2005112752/04 A RU 2005112752/04A RU 2005112752 A RU2005112752 A RU 2005112752A RU 2005112752 A RU2005112752 A RU 2005112752A
Authority
RU
Russia
Prior art keywords
alkyl
hydrogen
substituted
halogen
unsubstituted
Prior art date
Application number
RU2005112752/04A
Other languages
English (en)
Russian (ru)
Inventor
Эндрю Джон ИТЕРТОН (GB)
Эндрю Джон Итертон
Джерард Мартин Пол ГИБЛИН (GB)
Джерард Мартин Пол Гиблин
Карамджит Сингх ДЖАНДУ (GB)
Карамджит Сингх Джанду
Уилль м Леонард МИТЧЕЛЛ (GB)
Уилльям Леонард Митчелл
Алан НЭЙЛОР (GB)
Алан Нэйлор
Джованни ПАЛОМБИ (IT)
Джованни Паломби
Дерек Энтони РОЛИНГЗ (GB)
Дерек Энтони Ролингз
Брайан Питер СЛИНГСБИ (GB)
Брайан Питер Слингсби
Эндрю Ричард УИТТИНГТОН (GB)
Эндрю Ричард Уиттингтон
Ричард Ховард ГРИН (GB)
Ричард Ховард Грин
Original Assignee
Глэксо Груп Лимитед (GB)
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глэксо Груп Лимитед (GB), Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед (GB)
Publication of RU2005112752A publication Critical patent/RU2005112752A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2005112752/04A 2002-09-27 2003-09-25 Производные пиридина в качестве модуляторов рецептора сb2 RU2005112752A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0222493.9 2002-09-27
GBGB0222493.9A GB0222493D0 (en) 2002-09-27 2002-09-27 Compounds

Publications (1)

Publication Number Publication Date
RU2005112752A true RU2005112752A (ru) 2006-01-20

Family

ID=9944904

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005112752/04A RU2005112752A (ru) 2002-09-27 2003-09-25 Производные пиридина в качестве модуляторов рецептора сb2

Country Status (23)

Country Link
US (1) US20060240048A1 (enExample)
EP (1) EP1565442B1 (enExample)
JP (1) JP2006503845A (enExample)
KR (1) KR20050071514A (enExample)
CN (1) CN1703402A (enExample)
AR (1) AR041395A1 (enExample)
AT (1) ATE378317T1 (enExample)
AU (1) AU2003268907A1 (enExample)
BR (1) BR0314635A (enExample)
CA (1) CA2500231A1 (enExample)
DE (1) DE60317555T2 (enExample)
ES (1) ES2294313T3 (enExample)
GB (1) GB0222493D0 (enExample)
IS (1) IS7809A (enExample)
MA (1) MA27448A1 (enExample)
MX (1) MXPA05003263A (enExample)
NO (1) NO20052028L (enExample)
NZ (1) NZ538943A (enExample)
PL (1) PL375990A1 (enExample)
RU (1) RU2005112752A (enExample)
TW (1) TW200413321A (enExample)
WO (1) WO2004029026A1 (enExample)
ZA (1) ZA200502084B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2567390C2 (ru) * 2009-08-24 2015-11-10 Ньюралстем, Инк. Получение нейростимулирующего пиперазина

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
GB0402355D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402356D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402357D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
SE0401345D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
SE0401342D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
SE0401343D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine N oxide as scaffold
DK1753764T3 (da) 2004-06-09 2009-02-16 Glaxo Group Ltd Pyrrolopyridin-derivater
BRPI0614272A2 (pt) * 2005-08-09 2011-03-22 Glaxo Group Ltd derivados de imidazopiridinas como ligantes de receptores canabinóides
GB0519760D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
JP2009536613A (ja) * 2006-04-07 2009-10-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cb2受容体を調節する化合物
WO2008040649A2 (en) * 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
WO2008063625A2 (en) * 2006-11-20 2008-05-29 Adolor Corporation Pyridine compounds and methods of their use
BRPI0721268A2 (pt) * 2007-02-22 2013-01-15 Hemerus Medical Llc dispositivo de filtragem de fluido biol[ogico, mÉtodo para processar um fluido biolàgico, sistema de filtragem de fluido biolàgico
WO2010084767A1 (en) * 2009-01-22 2010-07-29 Raqualia Pharma Inc. N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity
CA2757188A1 (en) 2009-03-30 2010-10-07 Astellas Pharma Inc. Pyrimidine compound
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
JP2013048962A (ja) * 2012-12-12 2013-03-14 Hemerus Medical Llc 大容量の体液濾過装置
WO2018055640A1 (en) * 2016-09-22 2018-03-29 Srf Limited Process for the preparation of haloalkyl derivatives of nicotinic acid
MX2020012760A (es) 2018-06-27 2021-03-25 Hoffmann La Roche Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2.
EP3995155A1 (en) 2018-06-27 2022-05-11 F. Hoffmann-La Roche AG Radiolabeled cannabinoid receptor 2 ligand
EP3814328B1 (en) 2018-06-27 2026-03-11 F. Hoffmann-La Roche AG Novel azetidine-substituted pyridine compounds as inhibitors of cannabinoid receptor 2
WO2020025574A1 (en) 2018-08-03 2020-02-06 Bayer Aktiengesellschaft Process for the preparation of 6-(haloalkyl)-2-halo-5-acylpyridines and intermediates for this process
EP3666759A1 (en) 2018-12-10 2020-06-17 Bayer Aktiengesellschaft Preparation of 6-halo-2-(haloalkyl)-3-acylpyridines and intermediates therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112820A (en) * 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2567390C2 (ru) * 2009-08-24 2015-11-10 Ньюралстем, Инк. Получение нейростимулирующего пиперазина

Also Published As

Publication number Publication date
NZ538943A (en) 2007-01-26
EP1565442B1 (en) 2007-11-14
WO2004029026A1 (en) 2004-04-08
PL375990A1 (en) 2005-12-12
ATE378317T1 (de) 2007-11-15
TW200413321A (en) 2004-08-01
JP2006503845A (ja) 2006-02-02
ES2294313T3 (es) 2008-04-01
AR041395A1 (es) 2005-05-18
DE60317555T2 (de) 2008-10-23
CA2500231A1 (en) 2004-04-08
CN1703402A (zh) 2005-11-30
US20060240048A1 (en) 2006-10-26
MXPA05003263A (es) 2005-07-05
GB0222493D0 (en) 2002-11-06
DE60317555D1 (de) 2007-12-27
KR20050071514A (ko) 2005-07-07
ZA200502084B (en) 2006-02-22
NO20052028L (no) 2005-06-03
BR0314635A (pt) 2005-08-02
AU2003268907A1 (en) 2004-04-19
EP1565442A1 (en) 2005-08-24
MA27448A1 (fr) 2005-07-01
IS7809A (is) 2005-04-19

Similar Documents

Publication Publication Date Title
RU2375363C2 (ru) Пирролотриазиновые производные анилина, полезные в качестве ингибиторов киназы
RU2353616C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
CA2540214A1 (en) 2,4-dioxo-3-quinazolinylaryl sulfonylureas
JP2006503845A5 (enExample)
EP0860428A3 (en) Sulphonamide derivatives
EP1679069A4 (en) NEW PIPERIDINE DERIVATIVE
JP2008525417A5 (enExample)
AU2003267791A1 (en) Triazole compounds for the treatment of dysmenorrhoea
WO2003024441A1 (en) Novel use of tricyclic compound
EA200000731A1 (ru) Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
RU2008125196A (ru) Новые производные тиофена
AU757409B2 (en) Hiv integrase inhibitors
AR041395A1 (es) Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla
MXPA04003056A (es) Derivados de 4?piperidin-4-iliden-(3-carbamoilfenil)metil? benzamida y su uso para tratamiento de dolor, lesiones espinales o transtornos gastrointestinales.
RU2014113974A (ru) Замещенные бензиламины, их применение в медицине и, в частности, в лечении инфекций, вызванных вирусом гепатита с (hcv)
DK0510003T3 (da) Piperidin-og pyrrolidinderivater
AR024146A1 (es) Derivados de 4-fenil-pirimidina
JP2010513489A5 (enExample)
SE9904673D0 (sv) Novel compounds
AR043273A1 (es) Derivados de bifenilo, su uso, un proceso para prepararlos y medicamentos que los contienen.
CO5540303A2 (es) Derivados de 4-(fenil-piperidin-4-iliden-metil)-benzamida y su uso para el tratamiento del dolor, ansiedad o desordenes gastrointestinales
MXPA03010437A (es) Derivados de 4-(fenil-piperidin-4-iliden-metil)-benzamida y su uso para tratar dolor, ansiedad o transtornos gastrointestinales.
MXPA03010438A (es) Derivados de 4-(fenil-piperidin-4-iliden-metil)-benzamida y su uso para tratar dolor, ansiedad o transtornos gastrointestinales.
SE0101769D0 (sv) Novel compounds
BR0103180A (pt) Derivados do diazabiciclooctano e suas utilizações terapêuticas

Legal Events

Date Code Title Description
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20080812